$ANIK
Anika Therapeutics, Inc. Stock $anik

$anik Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000117184322001790 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$35.82M	$147.8M	$32.69M
YoY Change	9.58%	13.29%	9.79%
Cost Of Revenue	$17.69M	$64.85M	$15.94M
YoY Change	10.96%	5.57%	84.3%
Gross Profit	$18.13M	$82.94M	$16.75M
YoY Change	8.3%	20.16%	-20.73%
Gross Profit Margin	50.62%	56.12%	51.23%
Selling, General & Admin	$20.43M	$74.10M	$15.18M
YoY Change	34.6%	23.36%	24.02%
% of Gross Profit	112.67%	89.33%	90.65%
Research & Development	$6.000M	$27.33M	$7.630M
YoY Change	-21.36%	16.63%	87.01%
% of Gross Profit	33.09%	32.95%	45.57%
Depreciation & Amortization	$3.730M	$6.500M	$3.500M
YoY Change	6.57%	6.56%	128.76%
% of Gross Profit	20.57%	7.84%	20.9%
Operating Expenses	$27.26M	$101.4M	$22.81M
YoY Change	19.5%	21.47%	39.77%
Operating Profit	-$9.123M	$2.615M	-$6.065M
YoY Change	50.42%	-109.23%	-226.28%
Interest Expense	-$47.00K	-$188.0K	$12.31M
YoY Change	-100.38%	-37.75%	3319.44%
% of Operating Profit		-7.19%
Other Income/Expense, Net
YoY Change
Pretax Income	-$9.170M	$2.427M	-$18.14M
YoY Change	-49.45%	-108.48%	-451.55%
Income Tax	-$3.377M	-$1.707M	-$2.480M
% Of Pretax Income		-70.33%
Net Earnings	-$5.793M	$4.134M	-$15.66M
YoY Change	-63.0%	-117.24%	-486.5%
Net Earnings / Revenue	-16.17%	2.8%	-47.9%
Basic Earnings Per Share		$0.29	-$1.10
Diluted Earnings Per Share	-$401.3K	$0.28	-$1.10
COMMON SHARES
Basic Shares Outstanding	14.44M	14.40M	14.21M
Diluted Shares Outstanding		14.63M	14.28M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$94.39M	$94.39M	$98.30M
YoY Change	-3.98%	-3.98%	-46.84%
Cash & Equivalents	$94.39M	$94.39M	$95.82M
Short-Term Investments	$0.00	$0.00	$2.500M
Other Short-Term Assets	$8.289M	$8.289M	$8.800M
YoY Change	-5.81%	-5.81%	104.65%
Inventory	$36.01M	$36.01M	$46.21M
Prepaid Expenses
Receivables	$29.84M	$29.84M	$24.10M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$168.5M	$168.5M	$177.4M
YoY Change	-4.99%	-5.0%	-24.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$47.60M	$68.56M	$50.61M
YoY Change	-5.95%	-6.34%	-0.33%
Goodwill	$7.781M		$8.413M
YoY Change	-7.51%		9.34%
Intangibles	$82.38M		$91.16M
YoY Change	-9.63%		1101.81%
Long-Term Investments
YoY Change
Other Assets	$20.29M	$20.29M	$15.42M
YoY Change	31.55%	31.72%	106.2%
Total Long-Term Assets	$179.0M	$179.0M	$188.2M
YoY Change	-4.9%	-4.88%	95.24%
TOTAL ASSETS
Total Short-Term Assets	$168.5M	$168.5M	$177.4M
Total Long-Term Assets	$179.0M	$179.0M	$188.2M
Total Assets	$347.5M	$347.5M	$365.6M
YoY Change	-4.94%	-4.94%	10.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.633M	$7.633M	$8.984M
YoY Change	-15.04%	-15.19%	134.45%
Accrued Expenses	$17.66M	$17.66M	$14.60M
YoY Change	20.95%	20.95%	17.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$188.0K	$188.0K	$100.0K
YoY Change	88.0%	88.0%
Total Short-Term Liabilities	$29.80M	$29.80M	$36.87M
YoY Change	-19.18%	-19.25%	126.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.258M	$20.50M	$1.244M
YoY Change	1.13%	-53.83%	248.46%
Total Long-Term Liabilities	$1.258M	$20.50M	$1.244M
YoY Change	1.13%	-53.83%	248.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.80M	$29.80M	$36.87M
Total Long-Term Liabilities	$1.258M	$20.50M	$1.244M
Total Liabilities	$31.05M	$60.45M	$38.11M
YoY Change	-18.52%	-35.14%	129.12%
SHAREHOLDERS EQUITY
Retained Earnings	$225.6M		$221.4M
YoY Change	1.87%		-9.77%
Common Stock	$67.23M		$55.50M
YoY Change	21.13%		13.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$287.1M	$287.1M	$272.4M
YoY Change
Total Liabilities & Shareholders Equity	$347.5M	$347.5M	$365.6M
YoY Change	-4.94%	-4.94%	10.55%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$5.793M	$4.134M	-$15.66M
YoY Change	-63.0%	-117.24%	-486.5%
Depreciation, Depletion And Amortization	$3.730M	$6.500M	$3.500M
YoY Change	6.57%	6.56%	128.76%
Cash From Operating Activities	$4.472M	$8.397M	$2.590M
YoY Change	72.66%	-35.73%	-80.12%
INVESTING ACTIVITIES
Capital Expenditures	-$1.127M	$5.143M	-$450.0K
YoY Change	150.44%	215.91%	66.67%
Acquisitions		$476.0K
YoY Change		-99.5%
Other Investing Activities	-$113.0K	$2.025M	$17.25M
YoY Change	-100.66%	-102.91%	-58.22%
Cash From Investing Activities	-$1.240M	-$3.118M	$16.81M
YoY Change	-107.38%	-95.62%	-59.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	60.00K	-$6.779M	-28.11M
YoY Change	-100.21%	79.62%	-10139.29%
NET CHANGE
Cash From Operating Activities	4.472M	$8.397M	2.590M
Cash From Investing Activities	-1.240M	-$3.118M	16.81M
Cash From Financing Activities	60.00K	-$6.779M	-28.11M
Net Change In Cash	3.292M	-$1.431M	-8.710M
YoY Change	-137.8%	-97.68%	-116.03%
FREE CASH FLOW
Cash From Operating Activities	$4.472M	$8.397M	$2.590M
Capital Expenditures	-$1.127M	$5.143M	-$450.0K
Free Cash Flow	$5.599M	$3.254M	$3.040M
YoY Change	84.18%	-71.55%	-77.14%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6083000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4957000	USD
CY2021	anik	Amortization Of Acquisition Related Intangible Assets AmortizationOfAcquisitionRelatedIntangibleAssets	7837000	USD
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1442000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1523000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14441000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14441000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14329000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14329000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y6M
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94386000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	95817000	USD
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2501000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	29843000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24102000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	36010000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46209000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8289000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8754000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	168528000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	177383000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47602000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20957000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	22619000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20285000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15420000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	82382000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91157000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	7781000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8413000	USD
CY2021Q4	us-gaap	Assets Assets	347535000	USD
CY2020Q4	us-gaap	Assets Assets	365605000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7633000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8984000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	17847000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14793000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	4315000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	13090000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29795000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36867000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1258000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1244000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22320000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10157000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11895000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19240000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20879000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	144000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	143000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	67081000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	55355000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5718000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4542000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	225578000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	221444000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	287085000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	272400000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	347535000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	365605000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147794000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130457000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114610000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	64851000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	61431000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28747000	USD
CY2021	us-gaap	Gross Profit GrossProfit	82943000	USD
CY2020	us-gaap	Gross Profit GrossProfit	69026000	USD
CY2019	us-gaap	Gross Profit GrossProfit	85863000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27327000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23431000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16665000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	74096000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60063000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34950000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-21095000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28666000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	80328000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	97348000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	51615000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	2615000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-28322000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	34248000	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-188000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-302000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1873000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2427000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28624000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36121000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1707000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4642000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8928000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4134000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.93
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.89
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14401000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14222000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14121000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14634000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14222000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14374000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4134000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1176000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1356000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-372000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2958000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22626000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	26821000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	263612000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22151000	USD
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2019	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	6087000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	293000	USD
CY2019	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	30000000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-372000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	288378000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1524000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures	0	USD
CY2020	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	5386000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	262000	USD
CY2020	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	-0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1356000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	272400000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1128000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021	anik	Apic Sharebased Payment Arrangement Increase Decrease For Cost Recognition Benefit APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit	11085000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	486000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4134000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1176000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	287085000	USD
CY2020	anik	Amortization Of Acquisition Related Intangible Assets AmortizationOfAcquisitionRelatedIntangibleAssets	7381000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	4134000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-23982000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	27193000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	6480000	USD
CY2019	anik	Amortization Of Acquisition Related Intangible Assets AmortizationOfAcquisitionRelatedIntangibleAssets	1034000	USD
CY2021	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	6465000	USD
CY2020	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	11082000	USD
CY2019	anik	Amortization Of Acquisition Related Inventory Step Up AmortizationOfAcquisitionRelatedInventoryStepUp	0	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1708000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1531000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1179000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-21095000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-28666000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-993000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-265000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-927000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	600000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2439000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	389000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11085000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5386000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6087000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1766000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3543000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	794000	USD
CY2021	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	64000	USD
CY2020	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	549000	USD
CY2019	anik	Provision For Doubtful Accounts Net Of Recoveries ProvisionForDoubtfulAccountsNetOfRecoveries	-499000	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	6628000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	5490000	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1612000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	18000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	12000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	25000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6216000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5855000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1839000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6619000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14177000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5585000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1424000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1783000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1641000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1100000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	822000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	767000	USD
CY2021	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1626000	USD
CY2020	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1439000	USD
CY2019	anik	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1065000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3510000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-142000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3805000	USD
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1311000	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2072000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1085000	USD
CY2021	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-2780000	USD
CY2020	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	-522000	USD
CY2019	anik	Increase Decrease In Contingent Consideration IncreaseDecreaseInContingentConsideration	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8397000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13065000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	37005000	USD
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	476000	USD
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	94601000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-0	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2501000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	45000000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	146366000	USD
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20035000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	103848000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5143000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1628000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2827000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3118000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71264000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	39691000	USD
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	201000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	208000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	-0	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	50350000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	-0	USD
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	USD
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	30000000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	486000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	262000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	293000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1128000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1524000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22151000	USD
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7220000	USD
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4478000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	-0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6779000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3774000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8142000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	69000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	327000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-133000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1431000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-61646000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	68421000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95817000	USD
CY2021	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2020	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	476000	USD
CY2019	anik	Consideration For Acquisitions Included In Accounts Payable And Accrued Expenses ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses	0	USD
CY2021	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	0	USD
CY2020	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	69076000	USD
CY2019	anik	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	0	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	157463000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89042000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	94386000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	95817000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	157463000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1233000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	993000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9257000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	137000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><em style="font: inherit;">1.</em> Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation solutions provider focused on sports medicine and soft tissue repair, and Arthrosurface Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration, added higher-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The Company is subject to risks common to companies in the life sciences industry including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID-<em style="font: inherit;">19”</em>), and the Company is closely monitoring the impact of COVID-<em style="font: inherit;">19</em> on all aspects of its business, including how it will impact its customers, employees, suppliers, vendors, and business partners. The Company is unable to predict the specific impact that COVID-<em style="font: inherit;">19</em> <em style="font: inherit;"> may </em>have on its financial position and operations moving forward due to the numerous uncertainties. Any estimates made herein <em style="font: inherit;"> may </em>change as new events occur and additional information is obtained, and actual results could differ materially from any estimates made herein under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-<em style="font: inherit;">19.</em></p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 47pt;text-indent:-40pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"/> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 47pt; text-indent: -40pt;"><i>Reclassification of Prior Period Amounts</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: justify;">Certain prior period financial information has been reclassified to conform to current period presentation. The Company reclassified certain prior period amounts in the significant components of the Company’s deferred tax assets and liabilities as of <em style="font: inherit;"> December 31, 2020, </em>in Note <em style="font: inherit;">17,</em> <i>Income Taxes</i>, to conform to current year classification.</p>
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1200000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1300000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-400000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	300000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-300000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1523000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	962000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1525000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	156000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	635000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	92000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	86000	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	505000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	73000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	78000	USD
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	33000	USD
CY2021	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-72000	USD
CY2020	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	90000	USD
CY2019	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-31000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1442000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1523000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	962000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1000000.0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	200000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"><i>Concentration of Credit Risk </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with <em style="font: inherit;">two</em> major international financial institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> Mitek represented 41% and 44%, respectively, of the Company’s accounts receivable balance. <em style="font: inherit;">No</em> other single customer accounted for more than <em style="font: inherit;">10%</em> of accounts receivable in either period.</p>
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	2	pure
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42500000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2020	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	134410000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	157728000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12811000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	26731000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	33347000	USD
CY2021Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	55054000	USD
CY2020Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	61010000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	36010000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46209000	USD
CY2020	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-22984000	USD
CY2019	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	7144000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	16881000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	14852000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	11442000	USD
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	19044000	USD
CY2020Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	14801000	USD
CY2021Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	55054000	USD
CY2020Q4	anik	Inventory Raw Materials Work In Process And Finished Goods Net Of Reserve Total InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal	61010000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	9100000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6900000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	7694000	USD
CY2020	us-gaap	Depreciation Depreciation	6100000	USD
CY2019	us-gaap	Depreciation Depreciation	5000000.0	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	112736000	USD
CY2021Q4	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	3218000	USD
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	600000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	26536000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	82382000	USD
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P13Y
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	118859000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	87185000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	85300000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39583000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	34687000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47602000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2021	us-gaap	Depreciation Depreciation	6500000	USD
CY2020Q4	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	4227000	USD
CY2020	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	2439000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21036000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	91157000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P13Y
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7800000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7400000	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8413000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	25000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0	USD
CY2021	anik	Finance Lease Expense FinanceLeaseExpense	162000	USD
CY2020	anik	Finance Lease Expense FinanceLeaseExpense	210000	USD
CY2019	anik	Finance Lease Expense FinanceLeaseExpense	0	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2468000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	2383000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	2087000	USD
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-632000	USD
CY2020	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	719000	USD
CY2021	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	USD
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	42520000	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	-0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	42520000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	7781000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8413000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049	pure
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	143000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	185000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	19000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	6000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	319000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	264000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	216000	USD
CY2021	us-gaap	Lease Cost LeaseCost	2951000	USD
CY2020	us-gaap	Lease Cost LeaseCost	2857000	USD
CY2019	us-gaap	Lease Cost LeaseCost	2309000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y7M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041	pure
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049	pure
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2392000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2340000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	136000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	162000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2368000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	132000	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid Year One OperatingAndFinanceLeaseLiabilityToBePaidYearOne	2500000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2147000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	132000	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid Year Two OperatingAndFinanceLeaseLiabilityToBePaidYearTwo	2279000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2053000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	44000	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid Year Three OperatingAndFinanceLeaseLiabilityToBePaidYearThree	2097000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1918000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid Year Four OperatingAndFinanceLeaseLiabilityToBePaidYearFour	1918000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1578000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid Year Five OperatingAndFinanceLeaseLiabilityToBePaidYearFive	1578000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17871000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	anik	Operating And Finance Lease Liability To Be Paid After Year Five OperatingAndFinanceLeaseLiabilityToBePaidAfterYearFive	17871000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7169000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	14000	USD
CY2021Q4	anik	Operating And Finance Lease Liability Undiscounted Excess Amount OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount	7183000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19240000	USD
CY2021Q4	anik	Operating And Finance Lease Liability Non Current OperatingAndFinanceLeaseLiabilityNonCurrent	19346000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9523000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7345000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3590000	USD
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3438000	USD
CY2021Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	1961000	USD
CY2020Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	1429000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1059000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	996000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	17847000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	14793000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147794000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130457000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114610000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	147794000	USD
CY2021	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	130457000	USD
CY2020	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2019	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	100000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	114610000	USD
CY2019	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1	pure
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47602000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50613000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1900000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11085000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5386000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6087000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	100000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	200000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896819
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.50
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	529505
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	38.08
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31466
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	34.58
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	257000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	218865
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	44.77
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1175993
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	39.56
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	975000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	299451
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	43.64
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	264000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1175993
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	39.56
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	975000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2800000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8500000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	529505
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05	pure
CY2021	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	2000000.0	USD
CY2020	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	1700000	USD
CY2019	anik	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	800000	USD
CY2021	anik	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Per Option ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption	0.1480	pure
CY2020	anik	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Per Option ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption	0.1631	pure
CY2019	anik	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Per Option ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption	0.1473	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	38.20
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.02
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.40	pure
CY2019Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	50000000.0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2529000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-25722000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	38299000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4956000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2902000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2178000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	2427000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28624000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36121000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	494000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	357000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6245000	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-635000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-1970000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1884000	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	167000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	49000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	202000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	26000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-1564000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8331000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-553000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1980000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1086000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-426000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1070000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	324000	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-754000	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-28000	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-813000	USD
CY2021	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-1733000	USD
CY2020	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-3078000	USD
CY2019	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	597000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1707000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4642000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8928000	USD
CY2021Q4	anik	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4684000	USD
CY2020Q4	anik	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5147000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	282000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	229000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	491000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17772000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2453000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2004000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2822000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4775000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2782000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1742000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3022000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2485000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1236000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1037000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17419000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	-0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	857000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	17772000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16562000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	14770000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	13972000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8509000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8493000	USD
CY2021Q4	anik	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	4650000	USD
CY2020Q4	anik	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5111000	USD
CY2021Q4	anik	Deferred Tax Liabilities Accrued Expenses And Other DeferredTaxLiabilitiesAccruedExpensesAndOther	-0	USD
CY2020Q4	anik	Deferred Tax Liabilities Accrued Expenses And Other DeferredTaxLiabilitiesAccruedExpensesAndOther	881000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	27929000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	28457000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10157000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	11895000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.032	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.055	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.223	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.022	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.006	pure
CY2021	anik	Effective Income Tax Rate Reconciliation Share Based Compensation Section162m Limitation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent	0.087	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Share Based Compensation Section162m Limitation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent	0	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Share Based Compensation Section162m Limitation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent	0.003	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	pure
CY2021	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	0	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	-0.168	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Goodwill Impairment Percent EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent	0	pure
CY2021	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	-0.367	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	0.067	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Change In Fair Value Of Contingent Consideration Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent	0	pure
CY2021	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	-0.298	pure
CY2020	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	0.049	pure
CY2019	anik	Effective Income Tax Rate Reconciliation Change In State Apportionment Percent EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.284	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.022	pure
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.015	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.353	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.030	pure
CY2021	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	0.110	pure
CY2020	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	0.019	pure
CY2019	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	-0.012	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.704	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.162	pure
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.247	pure
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14401000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14222000
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14121000
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	233000
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2019	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	253000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14634000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14222000
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14374000

Files In Submission

Name	View Source	Status
0001171843-22-001790-index-headers.html	Edgar Link	pending
0001171843-22-001790-index.html	Edgar Link	pending
0001171843-22-001790.txt	Edgar Link	pending
0001171843-22-001790-xbrl.zip	Edgar Link	pending
anik-20211231.xsd	Edgar Link	pending
anik-20211231_cal.xml	Edgar Link	unprocessable
anik-20211231_def.xml	Edgar Link	unprocessable
anik-20211231_lab.xml	Edgar Link	unprocessable
anik-20211231_pre.xml	Edgar Link	unprocessable
anik20211231_10k.htm	Edgar Link	pending
anik20211231_10k_htm.xml	Edgar Link	completed
exh1015_01.jpg	Edgar Link	pending
exh1015_02.jpg	Edgar Link	pending
exh1015_03.jpg	Edgar Link	pending
exh1015_04.jpg	Edgar Link	pending
exh1015_05.jpg	Edgar Link	pending
exh1015_06.jpg	Edgar Link	pending
exh1015_07.jpg	Edgar Link	pending
exh1015_08.jpg	Edgar Link	pending
exh1015_09.jpg	Edgar Link	pending
exh1015_10.jpg	Edgar Link	pending
exh104a_01.jpg	Edgar Link	pending
exh104a_02.jpg	Edgar Link	pending
exh104a_03.jpg	Edgar Link	pending
exh104a_04.jpg	Edgar Link	pending
exh104a_05.jpg	Edgar Link	pending
exh104a_06.jpg	Edgar Link	pending
exh104a_07.jpg	Edgar Link	pending
exh104a_08.jpg	Edgar Link	pending
exh104a_09.jpg	Edgar Link	pending
exh104a_10.jpg	Edgar Link	pending
exh104a_11.jpg	Edgar Link	pending
exh104a_12.jpg	Edgar Link	pending
exh104a_13.jpg	Edgar Link	pending
exh104a_14.jpg	Edgar Link	pending
exh104a_15.jpg	Edgar Link	pending
exh104a_16.jpg	Edgar Link	pending
exh104a_17.jpg	Edgar Link	pending
exh104a_18.jpg	Edgar Link	pending
exh104a_19.jpg	Edgar Link	pending
exh104a_20.jpg	Edgar Link	pending
exh104a_21.jpg	Edgar Link	pending
exh104a_22.jpg	Edgar Link	pending
exh104a_23.jpg	Edgar Link	pending
exh104a_24.jpg	Edgar Link	pending
exh104a_25.jpg	Edgar Link	pending
exh104a_26.jpg	Edgar Link	pending
exh104a_27.jpg	Edgar Link	pending
exh104a_28.jpg	Edgar Link	pending
exh104a_29.jpg	Edgar Link	pending
exh104a_30.jpg	Edgar Link	pending
exh104a_31.jpg	Edgar Link	pending
exh104a_32.jpg	Edgar Link	pending
exh104a_33.jpg	Edgar Link	pending
exh104a_34.jpg	Edgar Link	pending
exh104a_35.jpg	Edgar Link	pending
exh104a_36.jpg	Edgar Link	pending
exh104b_01.jpg	Edgar Link	pending
exh104b_02.jpg	Edgar Link	pending
exh104b_03.jpg	Edgar Link	pending
exh104c_01.jpg	Edgar Link	pending
exh104c_02.jpg	Edgar Link	pending
exh104c_03.jpg	Edgar Link	pending
exh104c_04.jpg	Edgar Link	pending
exh104c_05.jpg	Edgar Link	pending
exh104c_06.jpg	Edgar Link	pending
exh104c_07.jpg	Edgar Link	pending
exh104c_08.jpg	Edgar Link	pending
exh104c_09.jpg	Edgar Link	pending
exh104c_10.jpg	Edgar Link	pending
exh104c_11.jpg	Edgar Link	pending
exh104c_12.jpg	Edgar Link	pending
exh104c_13.jpg	Edgar Link	pending
exh104c_14.jpg	Edgar Link	pending
exh104c_15.jpg	Edgar Link	pending
exh104c_16.jpg	Edgar Link	pending
exh104c_17.jpg	Edgar Link	pending
exh104c_18.jpg	Edgar Link	pending
exh104c_19.jpg	Edgar Link	pending
exh104c_20.jpg	Edgar Link	pending
exh104c_21.jpg	Edgar Link	pending
exh104c_22.jpg	Edgar Link	pending
exh104c_23.jpg	Edgar Link	pending
exh104c_24.jpg	Edgar Link	pending
exh104c_25.jpg	Edgar Link	pending
exh104c_26.jpg	Edgar Link	pending
exh104c_27.jpg	Edgar Link	pending
exh104c_28.jpg	Edgar Link	pending
exh104c_29.jpg	Edgar Link	pending
exh104c_30.jpg	Edgar Link	pending
exh104c_31.jpg	Edgar Link	pending
exh104c_32.jpg	Edgar Link	pending
exh104c_33.jpg	Edgar Link	pending
exh104c_34.jpg	Edgar Link	pending
exh104c_35.jpg	Edgar Link	pending
ex_342215.htm	Edgar Link	pending
ex_342238.htm	Edgar Link	pending
ex_342239.htm	Edgar Link	pending
ex_342244.htm	Edgar Link	pending
ex_342383.htm	Edgar Link	pending
ex_342384.htm	Edgar Link	pending
ex_342385.htm	Edgar Link	pending
ex_342386.htm	Edgar Link	pending
ex_342418.htm	Edgar Link	pending
ex_342419.htm	Edgar Link	pending
ex_342576.htm	Edgar Link	pending
ex_342577.htm	Edgar Link	pending
ex_342578.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
perf.jpg	Edgar Link	pending
portfolio1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIK
Anika Therapeutics, Inc. Stock $anik

2021 Q4 Form 10-K Financial Statement

#000117184322001790 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK Anika Therapeutics, Inc. Stock $anik

2021 Q4 Form 10-K Financial Statement

#000117184322001790 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK
Anika Therapeutics, Inc. Stock $anik